These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1677 related items for PubMed ID: 11289151
1. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5. Mitsiades N, Poulaki V, Mitsiades C, Tsokos M. Cancer Res; 2001 Mar 15; 61(6):2704-12. PubMed ID: 11289151 [Abstract] [Full Text] [Related]
2. Sensitivity of Ewing's sarcoma to TRAIL-induced apoptosis. Kontny HU, Hämmerle K, Klein R, Shayan P, Mackall CL, Niemeyer CM. Cell Death Differ; 2001 May 15; 8(5):506-14. PubMed ID: 11423911 [Abstract] [Full Text] [Related]
3. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand. Mitsiades N, Poulaki V, Tseleni-Balafouta S, Koutras DA, Stamenkovic I. Cancer Res; 2000 Aug 01; 60(15):4122-9. PubMed ID: 10945619 [Abstract] [Full Text] [Related]
4. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players. Hesry V, Piquet-Pellorce C, Travert M, Donaghy L, Jégou B, Patard JJ, Guillaudeux T. Prostate; 2006 Jun 15; 66(9):987-95. PubMed ID: 16541419 [Abstract] [Full Text] [Related]
5. Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Kazhdan I, Marciniak RA. Cancer Gene Ther; 2004 Oct 15; 11(10):691-8. PubMed ID: 15354201 [Abstract] [Full Text] [Related]
6. Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential. Hotta T, Suzuki H, Nagai S, Yamamoto K, Imakiire A, Takada E, Itoh M, Mizuguchi J. J Orthop Res; 2003 Sep 15; 21(5):949-57. PubMed ID: 12919886 [Abstract] [Full Text] [Related]
7. Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells. Lane D, Cartier A, L'Espérance S, Côté M, Rancourt C, Piché A. Gynecol Oncol; 2004 Jun 15; 93(3):594-604. PubMed ID: 15196850 [Abstract] [Full Text] [Related]
8. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Nimmanapalli R, Perkins CL, Orlando M, O'Bryan E, Nguyen D, Bhalla KN. Cancer Res; 2001 Jan 15; 61(2):759-63. PubMed ID: 11212279 [Abstract] [Full Text] [Related]
9. Regulation of the resistance to TRAIL-induced apoptosis as a new strategy for pancreatic cancer. Mori T, Doi R, Toyoda E, Koizumi M, Ito D, Kami K, Kida A, Masui T, Kawaguchi Y, Fujimoto K. Surgery; 2005 Jul 15; 138(1):71-7. PubMed ID: 16003319 [Abstract] [Full Text] [Related]
10. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells. Izeradjene K, Douglas L, Delaney A, Houghton JA. Clin Cancer Res; 2004 Oct 01; 10(19):6650-60. PubMed ID: 15475455 [Abstract] [Full Text] [Related]
11. Identification of interleukin 8 as an inhibitor of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in the ovarian carcinoma cell line OVCAR3. Abdollahi T, Robertson NM, Abdollahi A, Litwack G. Cancer Res; 2003 Aug 01; 63(15):4521-6. PubMed ID: 12907626 [Abstract] [Full Text] [Related]
12. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance. Ng CP, Zisman A, Bonavida B. Prostate; 2002 Dec 01; 53(4):286-99. PubMed ID: 12430140 [Abstract] [Full Text] [Related]
13. Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs. Tomek S, Horak P, Pribill I, Haller G, Rössler M, Zielinski CC, Pils D, Krainer M. Gynecol Oncol; 2004 Jul 01; 94(1):107-14. PubMed ID: 15262127 [Abstract] [Full Text] [Related]
14. Tumor necrosis factor-related apoptosis-inducing ligand-mediated proliferation of tumor cells with receptor-proximal apoptosis defects. Baader E, Toloczko A, Fuchs U, Schmid I, Beltinger C, Ehrhardt H, Debatin KM, Jeremias I. Cancer Res; 2005 Sep 01; 65(17):7888-95. PubMed ID: 16140959 [Abstract] [Full Text] [Related]
15. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Singh TR, Shankar S, Chen X, Asim M, Srivastava RK. Cancer Res; 2003 Sep 01; 63(17):5390-400. PubMed ID: 14500373 [Abstract] [Full Text] [Related]
16. Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma. Griffith TS, Fialkov JM, Scott DL, Azuhata T, Williams RD, Wall NR, Altieri DC, Sandler AD. Cancer Res; 2002 Jun 01; 62(11):3093-9. PubMed ID: 12036919 [Abstract] [Full Text] [Related]
17. Intracellular mechanisms mediating tocotrienol-induced apoptosis in neoplastic mammary epithelial cells. Sylvester PW, Shah S. Asia Pac J Clin Nutr; 2005 Jun 01; 14(4):366-73. PubMed ID: 16326643 [Abstract] [Full Text] [Related]
18. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling. Chen X, Kandasamy K, Srivastava RK. Cancer Res; 2003 Mar 01; 63(5):1059-66. PubMed ID: 12615723 [Abstract] [Full Text] [Related]
19. Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis. Petak I, Douglas L, Tillman DM, Vernes R, Houghton JA. Clin Cancer Res; 2000 Oct 01; 6(10):4119-27. PubMed ID: 11051265 [Abstract] [Full Text] [Related]
20. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ. J Immunol; 1998 Sep 15; 161(6):2833-40. PubMed ID: 9743343 [Abstract] [Full Text] [Related] Page: [Next] [New Search]